معرفی
Mahesh (Max) Parmar serves as Professor of Medical Statistics and Epidemiology and Director of both the MRC Clinical Trials Unit at UCL and the Institute of Clinical Trials and Methodology at University College London. With over 700 peer-reviewed publications, his work has directly influenced healthcare policy and clinical practice globally. His leadership has positioned the Unit as a world leader in resolving internationally important questions in infectious diseases, cancer, and neurodegenerative diseases.
His educational background includes:
- BSc (Hons) Mathematics from University of Exeter (1979-1982)
- MSc Fluid Mechanics and Statistics from University of Nottingham (1982-1983)
- DPhil from Oxford University (1983-1986)
Professor Parmar's research focuses on improving patient outcomes through innovative clinical trial design and methodology. He has pioneered multi-arm multi-stage platform trials, most notably through the STAMPEDE protocol, which has accelerated improvements in cancer treatment. His work spans cancer, infectious diseases, and neurodegenerative conditions, with emphasis on translating scientific research into patient benefits through methodological advances in study design, conduct, and analysis. He has made significant contributions to meta-analysis techniques and statistical methodologies for clinical trials.
Analysis of his recent publications reveals consistent focus on innovative trial design, particularly multi-arm multi-stage approaches across various disease areas. His work demonstrates strong emphasis on improving cancer treatment protocols, optimizing screening methods for early detection, and developing statistical methodologies for non-inferiority trials. The Bradford Hill Medal he received in 2024 recognizes his substantial contributions to medical statistics and epidemiology.
- Order of British Empire Medal (OBE) 2019
- Bradford Hill Medal 2024
As Director of the MRC Clinical Trials Unit at UCL, Parmar has led numerous major international trials that have directly impacted clinical practice. His leadership in the National Cancer Research Network significantly increased patient participation in cancer studies across England. He actively contributes to methodological development in clinical trials, with particular focus on adaptive designs and statistical approaches that accelerate therapeutic development. Parmar also plays a key role in training the next generation of clinical trialists through UCL's educational programs.
The MRC Clinical Trials Unit under Parmar's direction operates across multiple research themes including Cancer, Infections, Neurodegenerative Diseases, and Methodology. The Unit has been instrumental in developing and implementing innovative trial designs that have transformed how clinical research is conducted in multiple disease areas. Their work on the STAMPEDE platform trial has served as a model for numerous subsequent studies worldwide.
